Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7–6.4% in a Chinese population

Chung-Hao Li1,2, Yu-Tsung Chou1,2, Wei-Chen Shen2, Feng-Hwa Lu2,3,4, Yi-Ching Yang2,3, Jin-Shang Wu2,3,5,†, Chih-Jen Chang2,6,*†

1Department of Health Management Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 2Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 3Department of Family Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 4Department of Geriatrics and Gerontology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 5Department of Family Medicine, National Cheng Kung University Hospital, Dou-Liou Branch, College of Medicine, National Cheng Kung University, Yunlin, Taiwan, and 6Department of Family Medicine, Ditmanson Medical Foundation Chia-yi Christian Hospital, Chiayi, Taiwan

Keywords
Glycated hemoglobin, Non-alcoholic fatty liver disease, Prediabetes

*Correspondence
Chih-Jen Chang
Tel: +886-6-235-3535 (ext. 5355)
Fax: +886-6-238-6650
E-mail address:
changcj.ncku@gmail.com

J Diabetes Investig 2020; 11: 1336–1343
doi: 10.1111/jdi.13268

ABSTRACT
Aims/Introduction: Contrary to the results of the majority of studies on diabetes, there are some conflicting results regarding the relationship between non-alcoholic fatty liver disease (NAFLD) and prediabetes. No study has investigated the relationship between isolated glycated hemoglobin (HbA1c) in the range of 5.7–6.4% (HbA1c 5.7–6.4%) and NAFLD. Our aim was to investigate the effect of different glycemic statuses on NAFLD concomitantly categorized by fasting plasma glucose, 2-h plasma glucose and HbA1c levels.

Materials and Methods: NAFLD was classified into three groups by ultrasonographic examination results: normal, mild and moderate-to-severe. Glycemic status was divided into five groups: normoglycemia, isolated HbA1c 5.7–6.4%, impaired fasting glucose without impaired glucose tolerance (IGT), IGT and newly diagnosed diabetes. For multivariable logistic regression analyses, the outcome variable was the classified three grades of fatty changes in the liver after adjusting for other potential risk covariables.

Results: In this cross-sectional research, a total of 8,571 eligible individuals were enrolled and divided into three groups: 5,499 without fatty liver, 2,113 with mild NAFLD and 959 with moderate-to-severe NAFLD. Multivariable logistic regression analysis showed that IGT, impaired fasting glucose without IGT and isolated HbA1c 5.7–6.4% were associated with a higher risk of NAFLD in addition to newly diagnosed diabetes. Other positively predictive variables were male sex, obesity, overweight, central obesity, increased triglyceride and C-reactive protein >1 mg/L. Negatively associated factors were elevated high-density lipoprotein cholesterol levels.

Conclusions: Besides diabetes, the increased risks of different grades of NAFLD were found for prediabetic individuals categorized by impaired fasting glucose without IGT, IGT and isolated HbA1c 5.7–6.4%.

†These authors contributed equally to this work.
Received 26 November 2019; revised 5 March 2020; accepted 24 March 2020
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is characterized by an abnormal fat accumulation of ≥5%, which is referred to as hepatic steatosis, without excessive alcohol consumption and competing liver disease etiologies. NAFLD is the most common chronic liver disease in Western countries, with a global prevalence of 25.24%. NAFLD comprises a wide spectrum of histological abnormalities ranging from simple hepatic steatosis, non-alcoholic steatohepatitis, liver fibrosis, cirrhosis and eventually hepatocellular carcinoma. Many metabolic abnormalities have been found to be associated with NAFLD, and its main mechanism has been linked with insulin resistance. NAFLD has been found to coexist with diabetes mellitus, with a prevalence rate ranging between 49.6 and 74% in patients with diabetes mellitus. Additionally, diabetes mellitus has been considered to be a predictor of advanced stages of NAFLD. However, independent of obesity or other metabolic factors, NAFLD per se can also be a cause of insulin resistance, and has a direct role in the pathogenesis of diabetes mellitus.

Since 2009, in addition to pre-existing diabetes based on fasting plasma glucose (FPG) and 2-h plasma glucose (2-h PG) after an oral glucose tolerance test (OGTT), glycated hemoglobin (HbA1c) has been suggested to be a diagnostic criterion for the detection of diabetes and prediabetes. However, many reports have pointed out diagnostic discrepancies among the three criteria used to categorize hyperglycemia, which could indicate distinct pathophysiological processes and aspects of glucose metabolism different from impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). When compared with use of the OGTT, there are several advantages of using FPG and HbA1c values, including greater convenience and fewer day-to-day perturbations (or greater stability), respectively. The detection rate of diabetes mellitus did not decrease when HbA1c and FPG were combined relative to detection by 2-h PG after OGTT. Therefore, the 2-h PG values after OGTT have gradually become less frequently used, because it is more time-consuming, relatively expensive and requires that patients fast. These strategies might lead to loss of early interventions for some patients with undiagnosed diabetes, and loss of early prevention for NAFLD progression in the role of exacerbating the disease.

In contrast to the results of the majority of studies on diabetes mellitus, although the prevalence of NAFLD is higher in prediabetes individuals than in normoglycemic individuals, there are some conflicting results from studies that have explored the relationship between NAFLD and prediabetes, including IFG and IGT results. Yamada et al. found that fatty liver predicted IFG and diabetes mellitus on the basis of FPG level alone. In contrast, Mohan et al. concluded that NAFLD was only associated with diabetes mellitus, but not with IFG or IGT, a finding that was also discordant with the finding of Shiga et al. of NAFLD by 2-h PG levels. In addition to IFG and IGT, the status of NAFLD associated with the newly categorized isolated high HbA1c group, which might have been categorized into the normal glycemic population in the past, had not been previously understood. Nevertheless, the prevalence of prediabetes with NAFLD has been estimated to range from 44 to 62% in the USA, from 45 to 78% in Germany and 60% in Korea, which suggests a future epidemic of liver complications and the development of diabetes. The disappearance of fatty liver could also be a prognostic factor for regression from IGT to normal glucose regulation in individuals with NAFLD. Therefore, the aim of the present study was to investigate the relationship between NAFLD and different glycemic statuses concomitantly categorized by FPG, 2-h PG and HbA1c in a Chinese population.

METHODS
Study population
All individuals examined at the Health Examination Center of National Cheng Kung University Hospital, Tainan, Taiwan, from June 2001 to December 2010 were initially included. This retrospective study used a cross-sectional design without any personally identifiable information. None of the women participants were pregnant. Individuals of both sexes with significant alcohol drinking >140 g/week were first excluded according to the definitions of the American College of Gastroenterology and American Association for the Study of Liver Disease. The other exclusion criteria were as follows: (i) age <18 years; (ii) presence of hepatitis B, hepatitis C or other liver diseases, such as autoimmune hepatitis, drug-related liver disease, biliary hepatic injury, liver cirrhosis or any other self-reported liver disease; (iii) anemia (hemoglobin <13.0 g/dL in men and <12.0 g/dL in women) or hemolytic anemia and other self-reported hemoglobinopathies; (iv) serum creatinine >1.5 mg/dL; (v) congestive heart failure; (vi) diabetes and hypertension history; (vii) inflammation/infection disease, or white blood cell count <12/L and C-reactive protein (CRP) <7 mg/L; (viii) use of medications, such as oral hypoglycemic agents, antihypertensive agents, lipid-lowering agents, Chinese herbs, estrogen and steroids; (ix) obstructive sleep apnea; and (x) history of cancer. Habitual exercise was defined as vigorous exercise of at least three times per week. Finally, a total of 8,571 eligible individuals (64% men and 36% women) were included in the final analysis. The study protocol was approved by the Ethics Committee for Human Research at National Cheng Kung University Hospital, Taiwan (Approval No. ER-108-257).

Clinical parameter assessment
All participants completed a structured questionnaire containing questions regarding medical history, medication use and lifestyle habits, including alcohol consumption and regular exercise. While fasting and wearing only light indoor clothes without shoes, each participant had their bodyweight (to the nearest 0.1 kg) and height (to the nearest 0.1 cm) measured by a well-trained nurse, and the body mass index (BMI) was calculated.
Following the recommendations of the Health Promotion Administration in Taiwan, overweight and obesity were respectively defined as a 27 > BMI ≥ 24 and BMI ≥ 27 kg/m\(^2\). Waist circumference (WC) was measured from the midpoint between the lower rib margin and the iliac crest while the participants were standing with normal expiration at the end. WC ≥ 90 cm in men or ≥ 80 cm in women were defined as central obesity\(^2\). Blood pressure was measured in the right arm with a DINAMAP vital sign monitor (Model 1846SX DINAMAP Monitor; Critikon Inc., Tampa, FL, USA) in the sitting position after 10 min of rest, and the mean systolic and diastolic blood pressure (SBP and DBP) values of the two measurements were recorded. Newly categorized hypertension was defined as SBP >140 or DBP >90 mmHg without a history of hypertension\(^2\). After 10 h of fasting, a venous blood sample was drawn for the measurement of complete blood cell counts, FPG, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and CRP. The Fibrosis-4 score was calculated as (age [years] × AST) / (platelet count × ALT\(^1/2\)), and a lower cut-off value of Fibrosis-4 <1.30 was used for indicating no hepatic advanced fibrosis\(^2\). Then, 75 g of anhydrous glucose in 250 mL of water was administered over the course of 5 min. A blood sample to measure 2-h PG was collected 2-h after the participant began to drink the glucose solution. FPG and 2-h PG levels were determined by using the hexokinase method (Roche Diagnostische GmbH, Mannheim, Germany). HbA1c levels were measured by using ion-exchange high-performance liquid chromatography (HbA1c, BIO-RAD V-11 TURBO Hemoglobin HbA1c program; Bio-Rad Laboratories, Inc., Kent, UK). For our study purpose of the effect of glycemic statuses on the risk of NALFD, FPG, 2-h PG and HbA1c values were concomitantly used for categorizing hyperglycemic status into five categories according to the 2009 American Diabetes Association diagnostic criteria\(^5\), which were: (i) normoglycemic: FPG <5.6 mmol/L, 2-h PG <7.8 mmol/L and HbA1c <5.7%; (ii) isolated HbA1c 5.7–6.4%: FPG <5.6 mmol/L, 2-h PG <7.8 mmol/L and HbA1c 5.7–6.4%; (iii) IGT: 2-h PG of 7.8–11.0 mmol/L, FPG <7.0 mmol/L and HbA1c <6.5%; (iv) IFG without IGT: FPG of 5.7–7.0 mmol/L, 2-h PG <7.8 mmol/L and HbA1c <6.5%; and (v) newly diagnosed diabetes (NDD): FPG ≥7.0 mmol/L, 2-h PG ≥11.1 mmol/L or HbA1c ≥6.5%. The prediabetic status included groups 2, 3 and 4.

**Ultrasonography of the liver**

Abdominal ultrasonographic examination was carried out by two experienced radiologists who used high-resolution ultrasonography plus convex-type real-time electronic scanners (Xario SSA-660A; Toshiba, Nasu, Japan) and a 3.5-MHz linear transducer. Mild NAFLD was defined as a slight increase in liver echogenicity, mild attenuation in penetration by the ultrasound signal, and a slight decrease in the lucidity of the borders of the intrahepatic vessel walls and diaphragm. Moderate NAFLD was defined as a diffuse increase in liver echogenicity, greater attenuation in penetration by the ultrasound signal and a decrease in the visualization of the intrahepatic vessel walls, particularly the peripheral branches. Severe NAFLD was defined as a gross increase in liver echogenicity, greater attenuation in penetration by the ultrasound signal, and poor or no visualization of the hepatic vessels and diaphragm\(^2\). Considering that <1% of our study population was identified to be having severe NAFLD (just 72 participants), we merged the moderate and severe groups. Therefore, the extent of fatty changes in the liver on ultrasonography of all the recruited participants was categorized into the following three grades: none, mild and moderate-to-severe.

**Statistical analysis**

All data analyses were carried out using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). The comparisons of significant differences in unadjusted independent continuous variables were carried out using ANOVA with Scheffé’s post-hoc test, and the \(\chi^2\)-test was used for categorical variables. Although there was a specific order, but no exact spacing that existed between the three stages of our dependent variables based on ultrasonography, ordinal logistic regression analysis was not adapted because of the significant proportional odds \((P < 0.001)\). Instead, multivariable logistic regression models were further carried out to identify the classified three grades of fatty changes in the liver from the effect of different glycemic statuses, including isolated HbA1c ranging from 5.7 to 6.4% (HbA1c 5.7–6.4%), IGT, IFG without IGT and NDD, and other potential risk or metabolic covariates, such as age, sex, obesity, overweight, central obesity, hypertension, triglyceride, HDL-C, CRP and habitual exercise. Three kinds of models were shown in the adjustment of overweight, obesity and central obesity, either separately or simultaneously. \(P\)-values <0.05 were considered to be indicative of statistical significance.

**RESULTS**

Table 1 presents a comparison of the clinical characteristics of the participants who were divided into three groups by the different degree of fatty change in the liver based on abdominal ultrasonographic findings, including 5,499 participants without fatty liver, 2,113 participants with mild NAFLD and 959 participants with moderate-to-severe NAFLD. The participants with NAFLD had significantly different age, sex, BMI, SBP, DBP, WC, cholesterol, TG, HDL-C, CRP, AST, ALT, platelet, FGP, 2-h PG, HbA1c and habitual exercise. Scheffé’s post-hoc test showed that in the moderate-to-severe NAFLD group had higher values of BMI, SBP, DBP, WC, TG, CRP, AST, ALT, FGP, 2-h PG, HbA1c and lower values of HDL-C than the mild group. In this recruited study population, the proportion without an advanced degree of fibrosis predicted by Fibrosis-4 scores among these three groups was not significantly different. In addition, to clarify the effect of the metabolic categories, especially regarding the five glycemic statuses (the distribution
is shown in Figure 1), there were also significant differences between these three groups, as seen in Table 1.

In Table 2, multivariable logistic regression analysis adjusted in addition to glycemic parameters for other reported potential factors subsequently showed that each prediabetes status and diabetes status was associated with a higher risk of NAFLD. Although obesity and overweight were controlled for in model 1, and central obesity was controlled for in model 2, each prediabetes status was significantly persisted and associated with an increased risk of NAFLD after adjustment, including male participants, and increased triglyceride and CRP levels. In contrast, elevated HDL-C levels were associated with lower risks of NAFLD. In model 3, when obesity, overweight and central obesity were considered concomitantly, we still found a consistent tendency of the odds ratios of the remaining variables toward prediction of developing NAFLD.

### DISCUSSION

This is the first study to show a relationship between different grades of NAFLD and prediabetes categorized concomitantly by HbA1c, FPG and 2-h PG levels. Independent of other metabolic risk and lifestyle factors, in addition to participants with NDD, we found that participants with IFG and IGT had higher risks of NAFLD. Furthermore, the present study showed that NAFLD was significantly associated with individuals suffering from chronic hyperglycemic disease with isolated HbA1c 5.7–6.4%, which was previously categorized into the normal glycemic status and is therefore being ignored or not being studied.

Previously, the association between fatty liver and prediabetes with IFG or IGT was inconsistent, not to mention that there was a lack of evidence with isolated HbA1c 5.7–6.4%. NAFLD was more prevalent in individuals with prediabetes than in normoglycemic individuals. However, Rajput et al.

### Table 1 | Comparison of clinical characteristics among participants with the different ultrasound-based grading of the extent of fatty change in the liver

| Variables | NAFLD | Post-hoc test** |
|-----------|-------|----------------|
| Age (years) | 1. None: 45.65 ± 12.61 | <0.001 | a, b |
| | (n = 5,499) | 2. Mild: 49.17 ± 11.15 | | |
| | (n = 2,113) | 3. Moderate-to-severe: 48.23 ± 11.11 | | |
| | (n = 959) |
| Sex, male (n/ratio) | 3,114/566 | <0.001 | NA |
| BMI (kg/m²) | 2.72 ± 2.71 | <0.001 | a, b, c |
| WC (cm) | 79.01 ± 8.54 | <0.001 | a, b, c |
| SBP (mmHg) | 113.98 ± 15.26 | <0.001 | a, b, c |
| DBP (mmHg) | 67.36 ± 9.86 | <0.001 | a, b, c |
| Cholesterol (mmol/L) | 5.04 ± 0.93 | <0.001 | a, b |
| Triglyceride (mmol/L) | 1.22 ± 0.71 | <0.001 | a, b, c |
| HDL-C (mmol/L) | 1.37 ± 0.36 | <0.001 | a, b, c |
| CRP (mg/L) | 1.24 ± 1.55 | <0.001 | a, b, c |
| AST (U/L) | 22.73 ± 8.33 | <0.001 | a, b, c |
| ALT (U/L) | 23.52 ± 14.27 | <0.001 | a, b, c |
| Platelet (10⁹/µL) | 248.37 ± 54.87 | <0.001 | a, b |
| FIB-4 index score³, ≥1.3 (n/ratio) | 1,003/182 | <0.001 | a, b, c |
| FPG (mmol/L) | 48.7 ± 0.76 | <0.001 | a, b, c |
| 2h-PG (mmol/L) | 5.51 ± 0.54 | <0.001 | a, b, c |
| HbA1c (%) | 5.51 ± 0.54 | <0.001 | a, b, c |
| Different glycemic status | | | |
| Normoglycemic (n/ratio) | 3,551/609 | <0.001 | NA |
| Isolated HbA1c 5.7–6.4%³ (n/ratio) | 977/178 | 0.038 | NA |
| IGT² (n/ratio) | 727/132 | 0.038 | NA |
| IFG without IGT² (n/ratio) | 224/41 | 0.038 | NA |
| NDD (n/ratio) | 220/40 | 0.038 | NA |
| Habitual exercise⁷ (n/ratio) | 452/82 | 0.038 | NA |

Data are presented as the mean ± standard deviation or numbers/ratio. *P < 0.05, for ANOVA or χ²-tests. **P < 0.05, analysis of continuous variables with Scheffé’s post-hoc tests: a–1 versus 2, b–1 versus 3, c–2 versus 3. Fibrosis-4 (FIB-4) was calculated using the equation: (age × aspartate transaminase) / (platelet counts × alanine aminotransferase)¹². ¹Prediabetes: total distributions as shown in Figure 1. ²Defined as exercise at least three times per week. ³Fibrosis-4 (FIB-4) was calculated using the equation: (age × aspartate transaminase) / (platelet counts × alanine aminotransferase). ⁴Defined as exercise at least three times per week. ²Post-hoc test: a, b, c.
did not show the respective effect of IFG or IGT. Yamada et al.16 concluded that fatty liver was significantly associated with IFG patients; however, the study only had fasting glucose data, but no 2-h PG data. In contrast, Shiga et al.14 showed that NAFLD was clearly related to 2-h PG, but not to FPG. Mohan et al.15 found that NAFLD was only associated with diabetes mellitus, but not with IFG or IGT, which was explained by the small sample size of their prediabetes individuals. Although Shiga et al.14 pointed out the important relationship of 2-h PG, but not of FPG, with NAFLD, they should have noted if there were confounding effects, because the significant adjusted findings of calculated insulin resistance to NAFLD by Shiga et al.14 and by Mohan et al.15 were determined by FPG.

Academically, individuals with isolated IFG predominantly showed hepatic insulin resistance, whereas those with isolated IGT showed moderate-to-severe muscle insulin resistance28. In addition to skeletal muscle insulin resistance accompanying insulin resistance at other sites, accumulated fat in the liver is frequently accompanied by hepatic insulin resistance, but there is considerable debate regarding whether or not this correlation is causal29.

A major underlying mechanism of NAFLD is insulin resistance4 because of the findings of increased gluconeogenesis and glycogenolysis in the liver, as well as reduced glucose disposal in peripheral muscles, which exacerbates hyperglycemia and consequently hyperinsulinemia, and the findings of upregulated lipogenic factors and promotion of hepatic lipogenesis, which contribute to development of NAFLD7. HbA1c is a marker representing the mean glucose concentration reflecting the cumulative glycemic history over the past 2–3 months30. Among individuals with normal oral glucose tolerance, but isolated high HbA1c, Fu et al.10 found that they showed impaired early-phase β-cell dysfunction and increased generalized insulin resistance. Additionally, underlying systemic insulin resistance resulting in hyperinsulinemia31 might reasonably explain our finding that prediabetes with HbA1c 5.7–6.4% significantly increased the risk for NAFLD, which is similar to the finding of Giulio et al. of NAFLD in lean individuals with normal glucose tolerance4. Therefore, irrespective of IFG or IGT, prediabetes classified according to HbA1c 5.7–6.4% not only represents a chronic overt hyperglycemic state with fewer day-to-day fluctuations11, but also contributes to the development of NAFLD in a pathophysiological manner.

Figure 1 | Except for normoglycemic (n = 4,385) and newly diagnosed diabetes (n = 635) individuals, the Venn diagram represents different domains and agreements of prediabetes. A1c, glycated hemoglobin; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.

Taken together, our work shows for the first time that NAFLD groups presented with both significant IFG and IGT manifestation after adjusting for other metabolic risk factors. Additionally, although the sample size of the IFG without IGT group in the present study was smaller than that of the IGT group, the odds ratio for NAFLD was somewhat greater in the IFG without IGT group than that in the IGT group, which highlighted the importance of investigating NAFLD with hepatic insulin resistance in future research.

Despite conflicting evidence for sex as a risk factor for NAFLD32, the present study showed that male sex was associated with a higher risk of developing NAFLD. When compared with premenopausal women (data not shown) who were understood to have a protective effect of estrogen against development of NAFLD, male sex was still associated with an increased risk of developing NAFLD32.

Obesity is an important underlying cause of NAFLD, and BMI is believed to be correlated with NAFLD33. WC is another anthropometric index that is a strong predictor of the presence of NAFLD33,34. As neither BMI nor WC could replace visceral fat adiposity as the most vital predictor of NAFLD34, we concomitantly used these two predictors for final adjustment and still found that they were highly independent predictors of NAFLD. Otherwise, obesity-related adipose tissue dysfunction or insulin resistance could contribute to a pro-inflammatory state with increased cytokines35. As we had initially excluded individuals with inflammation or signs of infection, the present study showed a positive association of CRP ≥1 mg/L, which was consistent with the finding of a previous study that showed increased levels of tumor necrosis factor-alpha and interleukin-6 in NAFLD patients35,36.

The non-significant difference of the proportion of advanced fibrosis among the three grades of fatty changes in the liver indicates that after our strict exclusion criteria, the present study population was relatively healthy, thereby minimizing the effect of confounders and improving our research for exploring the relationship between hyperglycemic and NAFLD parameters. Our findings related to the role of lipid profiles in NAFLD were consistent with those of other studies in which increased triglyceride levels increased the risk of NAFLD and increased HDL levels decreased the risk37,38. Habitual exercise will cause
Table 2 | Adjusted odds ratio (OR) and 95% confidence interval (CI) of variables for the risk of mild and moderate-to-severe fatty liver based on multivariable logistic regression analysis.

| Variables                        | Model 1 Mild vs no NAFLD | Model 1 Moderate-to-severe vs no NAFLD | Model 2 Mild vs no NAFLD | Model 2 Moderate-to-severe vs no NAFLD | Model 3 Mild vs no NAFLD | Model 3 Moderate-to-severe vs no NAFLD |
|----------------------------------|--------------------------|----------------------------------------|--------------------------|----------------------------------------|--------------------------|----------------------------------------|
| Age                              | 1.01 (1.00–1.01)*        | 1.00 (0.99–1.00)                        | 1.00 (1.00–1.01)          | 0.98 (0.97–0.99)                       | 1.01 (1.00–1.01)          | 0.99 (0.98–1.00)                       |
| Sex (male vs female)             | 1.65 (1.44–1.90)**       | 1.57 (1.28–1.92)**                      | 2.26 (1.97–2.58)**        | 2.26 (1.85–2.75)**                     | 1.82 (1.58–2.09)**        | 1.84 (1.50–2.27)**                     |
| Overweight (yes vs no)†          | 4.28 (3.74–4.90)**       | 6.61 (5.10–8.56)**                      |                           |                                        | 3.39 (2.93–3.92)          | 4.00 (3.03–5.28)**                     |
| Obesity (yes vs no)‡             | 12.16 (10.23–14.45)**    | 43.85 (33.35–57.33)**                   |                           |                                        | 7.13 (5.80–8.76)          | 16.16 (11.80–22.13)**                  |
| Central Obesity (yes vs no)‡     |                           |                                        | 4.85 (4.29–5.48)**        | 13.33 (11.06–16.06)**                | 1.99 (1.71–2.31)          | 3.68 (2.94–4.62)**                     |
| Hypertension (yes vs no)§         | 1.19 (0.99–1.44)         | 1.26 (1.00–1.61)                        | 1.19 (0.99–1.42)          | 1.31 (1.04–1.65)                      | 1.15 (0.95–1.38)          | 1.19 (0.93–1.51)                       |
| Triglyceride (mmol/L, ≥1.7 vs <1.7) | 2.33 (2.04–2.66)**     | 3.44 (2.88–4.12)                        | 2.41 (2.12–2.74)**        | 3.52 (2.95–4.19)**                    | 2.30 (2.01–2.63)**        | 3.39 (2.83–4.07)**                     |
| HDL-C (mmol/L, ≥1 vs <1)         | 0.66 (0.58–0.76)**       | 0.55 (0.45–0.66)**                      | 0.63 (0.55–0.73)**        | 0.51 (0.43–0.62)**                     | 0.68 (0.59–0.78)**        | 0.57 (0.47–0.69)**                     |
| CRP (mg/L, ≥1 vs <1)             | 1.43 (1.26–1.62)**       | 1.54 (1.28–1.86)**                      | 1.56 (1.38–1.76)**        | 1.77 (1.48–2.13)**                    | 1.39 (1.23–1.58)**        | 1.47 (1.21–1.78)**                     |
| Prediabetes                      |                           |                                        |                           |                                        |                           |                                        |
| Isolated HbA1c 5.7%–64% vs normoglycemic | 1.53 (1.31–1.79)** | 1.58 (1.24–2.01)**                      | 1.62 (1.39–1.89)**        | 1.69 (1.34–2.14)**                    | 1.51 (1.29–1.77)**        | 1.53 (1.20–1.95)**                     |
| IGT vs normoglycemic             | 1.65 (1.40–1.96)**       | 2.80 (2.22–3.52)**                      | 1.69 (1.43–1.99)**        | 2.90 (2.32–3.64)**                    | 1.62 (1.36–1.92)**        | 2.70 (2.14–3.41)**                     |
| IFG without IGT vs normoglycemic  | 1.97 (1.53–2.52)**       | 3.10 (2.22–4.33)**                      | 2.14 (1.67–2.73)**        | 3.31 (2.38–4.60)**                    | 1.92 (1.50–2.47)**        | 3.03 (2.16–4.24)**                     |
| NDD vs normoglycemic             | 2.49 (1.96–3.16)**       | 5.23 (3.88–7.05)**                      | 2.37 (1.88–2.99)**        | 4.97 (3.73–6.64)**                    | 2.37 (1.86–3.01)**        | 4.80 (3.55–6.49)**                     |
| Habitual exercise, ≥3 vs <3 times/week | 0.73 (0.58–0.92)   | 0.73 (0.53–1.02)                         | 0.83 (0.67–1.04)          | 0.88 (0.64–1.22)                      | 0.76 (0.60–0.95)**        | 0.76 (0.54–1.06)**                     |

*P < 0.05, **P < 0.001. †Overweight was defined as 27 > BMI ≥ 24; Obesity was defined as BMI ≥ 27. ‡Central obesity was defined as waist circumference ≥90 cm for male and ≥80 cm for female. §Hypertension was defined as mean systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. ¶Habitual exercise was defined as exercise at least three times per week. CRP, C-reactive protein; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NAFLD, non-alcoholic fatty liver disease; NDD, newly diagnosed diabetes.
increased levels of HDL\(^\text{20}\); however, both of which were inconsistent with the finding of the decreased risk of NAFLD. This insignificant result of habitual exercise on NAFLD might be related to the small sample size of that in each group (shown in Table 1). In addition, when we changed the classification of fatty liver to with versus without, the effect of habitual exercise on decreasing fatty liver was significant (adjusted odds 0.76, 95% confidence interval 0.61–0.95, \(P = 0.014\)), which was in concordance with the results of a previous study\(^\text{40}\).

The difference between age and different grades of NAFLD was not significant before adjustment by Scheffe’s post-hoc test initially shown in Table 1. In Table 2, although the effects of age on NAFLD between the three models under adjustments in the present study were not consistent with the findings of another study\(^\text{41}\), inclusion of age might lead to collinearity with highly associated variables, which might be mediated by intermediate parameters.

This large study cohort had some limitations. The first was the cross-sectional design, which meant that it was not possible to determine if associations of factors with NAFLD were causal. Second, the participants were limited to a Chinese population, so the findings might not be applicable to other population groups; however, it complemented the research between different ethnic groups. Third, the present data were extracted from a health management center, and although we applied many exclusion criteria to minimize confounding effects, the results should be interpreted carefully when trying to apply them to the general population. Finally, although abdominal ultrasonographic examination might not be the gold standard for NAFLD diagnosis, it is the most commonly used tool, with 60–94% sensitivity and 66–95% specificity\(^\text{7}\). Our data collection and interpretation were also limited to two experienced radiologists to minimize operator-dependent biases.

In conclusion, the present study results showed that prediabetes status characterized by HbA1c 5.7–6.4%, in addition to characterization by NDD, IFG without IGT and IGT, was also associated with an increased risk of NAFLD. In addition to the traditionally used FPG or 2-h PG, individuals who have been diagnosed as having NAFLD should also have their HbA1c status checked, which might provide additional evidence that prediabetes status can be established on the basis of isolated HbA1c 5.7–6.4%.

ACKNOWLEDGMENTS

We are grateful to Dr Sheng-Hsiang Lin and Ms Chih-Hui Hsu for providing statistical consulting services from the Biostatistics Consulting Center, Clinical Medicine Research Center, National Cheng Kung University Hospital. The authors thank Enago (https://www.enago.tw/) for assistance editing the manuscript. This research was funded by the National Cheng Kung University Hospital, Taiwan (NCKUH-10903009).

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–2023.
2. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
3. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17(Suppl): S186–S190.
4. Marchesini G, Brizi M, Manselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–455.
5. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32–42.
6. Bazick J, Donithan M, Neuschwander-Tetri BA, et al. Clinical Model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care 2015; 38: 1347–1355.
7. Leite NC, Villela-Nogueira CA, Cardoso CR, et al. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20: 8377–8392.
8. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327–1334.
9. Leal J, Morrow LM, Khurshid W, et al. Decision models of prediabetes populations: a systematic review. Diabetes Obesity Metab 2019; 21: 1558–1569.
10. Fu Q, Sun M, Wang Z, et al. Impaired beta-cell function and decreased insulin sensitivity in subjects with normal oral glucose tolerance but isolated high glycosylated hemoglobin. Endocrine J 2018; 65: 13–22.
11. Classification and diagnosis of diabetes. Diabetes Care 2017; 40: S11–S24.
12. Wu S, Shi Y, Pan Y, et al. Glycated hemoglobin independently or in combination with fasting plasma glucose versus oral glucose tolerance test to detect abnormal glycometabolism in acute ischemic stroke: a Chinese cross-sectional study. BMC Neurol 2014; 14: 177.
13. Rajput R, Ahiawat P. Prevalence and predictors of non-alcoholic fatty liver disease in prediabetes. Diabetes Metab Syndr 2019; 13: 2957–2960.
14. Shiga T, Moriyoshi Y, Nagahara H, et al. Nonalcoholic fatty liver is a risk factor for postprandial hyperglycemia, but not for impaired fasting glucose. J Gastroenterol 2009; 44: 757–764.
15. Mohan V, Farooq S, Deepa M, et al. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009; 84: 84–91.
21. Son JI, Rhee SY, Woo JT, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25: 352–356.

17. Le P, Chaitoff A, Rothenberg MB, et al. Trends in prevalence of nonalcoholic fatty liver disease in US adults with prediabetes. J Gen Intern Med 2019; 34: 2336–2338.

20. Chalasani N, Younossi Z, Lavine JE, et al. Fatty liver index is a predictor of incident diabetes in patients with prediabetes: the PREDAPS study. PLoS One 2018; 13: e0198327.

19. Ogata C, Ohmoto-Sekine Y, Tanabe M, et al. Prognostic factors for regression from impaired glucose tolerance to normal glucose regulation in Japanese patients with nonalcoholic fatty liver disease. Intern Med 2014; 53: 1401–1406.

20. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–357.

21. Son JI, Rhee SY, Woo JT, et al. Hemoglobin a1c may be an inadequate diagnostic tool for diabetes mellitus in anemic subjects. Diabetes Metab J 2013; 37: 343–348.

22. Heath EH. ACSM’s guidelines for exercise testing and prescription, 7th Edition. Med Sci Sports Exercise 2005; 37: 2018.

23. Pan WH, Lee MS, Chuang SY, et al. Obesity pandemic, correlated factors and guidelines to define, screen and manage obesity in Taiwan. Obesity Rev 2008; 9(Suppl 1): 22–31.

24. Bassett J. International Diabetes Institute, World Health Organization, Regional Office for the Western Pacific, International Association for the Study of Obesity, International Obesity Task force. The Asia-Pacific perspective: redefining obesity and its treatment. Australia: Health Communications Australia, 2000.

25. Jones DW, Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 2004; 43: 1–3.

26. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol 2018; 68: 305–315.

27. Strauss S, Gavish E, Gottlieb P, et al. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol 2007; 189: W320–W323.

28. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753–739.

29. Farese RV Jr, Zechner R, Newgard CB, et al. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 2012; 15: 570–573.

30. Sherwani SI, Khan HA, Ekzhaimy A, et al. Significance of HbA1c Test in diagnosis and prognosis of diabetic patients. Biomarker Insights 2016; 11: 95–104.

31. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519–1523.

32. Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59: 1406–1414.

33. Ha Y, Seo N, Shim JH, et al. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: a case-control study. J Gastroenterol Hepatol 2015; 30: 1666–1672.

34. Almeida NS, Rocha R, Cotrim HP, et al. Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: a review. World J Hepatol 2018; 10: 695–701.

35. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038–1048.

36. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24: 695–708.

37. Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014; 510: 84–91.

38. Ren XY, Shi D, Ding J, et al. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study. Lipids Health Dis 2019; 18: 47.

39. Kelley GA, Kelley KS. Effects of diet, aerobic exercise, or both on non-HDL-C in adults: a meta-analysis of randomized controlled trials. Cholesterol 2012; 2012: 840935.

40. Qi X, Cai X, Sun Z, et al. Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol 2017; 10: 701–713.

41. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356–1362.